Utilization Patterns of Pulmicort [budesonide] Hydro Fluoroaklane (HFA) Pressurized Metered-Dose Inhaler (pMDI) in Real Life Practice.

Trial Profile

Utilization Patterns of Pulmicort [budesonide] Hydro Fluoroaklane (HFA) Pressurized Metered-Dose Inhaler (pMDI) in Real Life Practice.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2010

At a glance

  • Drugs Budesonide (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 30 Nov 2010 Last checked against ClinicalTrials.gov record.
    • 30 Nov 2010 Actual end date changed from (Mar 2009) to (Feb 2009) as reported by ClinicalTrials.gov.
    • 06 Mar 2009 Actual patient number (60) reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top